{"nctId":"NCT00224120","briefTitle":"A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo","startDateStruct":{"date":"2005-05"},"conditions":["Benign Prostatic Hyperplasia"],"count":462,"armGroups":[{"label":"Silodosin","type":"EXPERIMENTAL","interventionNames":["Drug: Silodosin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Silodosin","otherNames":["Rapaflo"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males in good general health and at least 50 years of age, with symptoms of moderate to severe BPH.\n\nExclusion Criteria:\n\n* Medical conditions that would confound the efficacy evaluation.\n* Medical conditions in which it would be unsafe to use an alpha-blocker.\n* The use of concomitant drugs that would confound the efficacy evaluation.\n* The use of concomitant drugs that would be unsafe with this alpha-blocker.","healthyVolunteers":false,"sex":"MALE","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Measuring Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks","description":"International prostate symptom score: Measuring prostate signs and symptoms asociated with benign prostatic hyperplasia on a 0 to 35 scale; 0 best, 35 worst symptoms","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":"4.88"},{"groupId":"OG001","value":"21.2","spread":"4.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","spread":"6.54"},{"groupId":"OG001","value":"-3.4","spread":"5.83"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Maximum Urine Flow Rate (Qmax) at 12 Weeks","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"2.48"},{"groupId":"OG001","value":"8.7","spread":"2.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"4.53"},{"groupId":"OG001","value":"1.9","spread":"4.82"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":233},"commonTop":["Retrograde ejaculation","Dizziness","Diarrhoea","Nasopharyngitis","Orthostatic hypotension"]}}}